Title: Thoracic Malignancies Tumor Registry: THOR-1
Purpose of Study: The objective of this project is to collect clinical as well as genomic data on lung cancer patients in our practice in order to improve our understanding of thoracic malignancies in our community as well as disparities that may affect patient access to treatment.
Aim 1. Characterize clinical features of patients with thoracic malignancies who present to our clinic.
Aim 2. Characterize genomic features of patients with thoracic malignancies.
Aim 3. Characterize geographic and economic disparities in biomarker testing
Basic Eligibility Criteria:
Inclusion:
Histologically proven diagnosis of non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma, mesothelioma, neuroendocrine tumor, or carcinoma of unknown primary consistent with the presentation of a primary thoracic malignancy. Patients clinically suspected to have a thoracic malignancy are also eligible while undergoing workup and treatment, for example, patients who undergo thymectomy for suspected thymoma in the setting of an autoimmune diagnosis, or patients receiving radiation for a lung nodule clinically suspected to be lung cancer but not biopsy proven.
18 years of age or older.
Ability to understand and the willingness to sign a written informed consent document
Exclusion:
Pregnant females
Subjects incapable of understanding the items listed in the ICF and consent process
Subjects with a history of or known psychiatric illness that deems them unable to consent
For More Information
If you're interested in participating in this clinical trial, please complete the form below. A member of the Cancer Care Northwest Clinical Research Department will review your information and contact you shortly.
